We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
Requests for offprints should be sent to: / Les demandes de tirés-a-part doivent être adressées à: Anita L. Kozyrskyj, PhD, Department of Community Health Sciences, Faculty of Medicine, Manitoba Centre for Health Policy, 408–727 McDermot Ave., Winnipeg, MBR3E 3P5. ([email protected])
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Type
Editorials: Perspectives on the Romanow Commission Report/Éditoriaux : Perspectives sur le Rapport de la Commission Romanow
1Commission on the Future of Health Care in Canada. Building on values: the future of health care in Canada—final report. Ottawa: Government of Canada; 2002. p. 190.Google Scholar
2
2Taylor, MG. Health insurance and Canadian public policy: the seven decisions that created the Canadian health insurance system and their outcomes. 2nd ed.Montreal: McGill-Queen's University Press; 1987.Google Scholar
3
3Millar, WJ. Disparities in prescription drug insurance coverage. Health Rep1999;10:11–21.Google ScholarPubMed
4
4Canadian Institute for Health Information. Drug expenditure in Canada, 1985–2001. Ottawa: Canadian Institute for Health Information; 2002.Google Scholar
5
5Willison, D, Grootendorst, P, Hurley, J. Variation in pharmacare coverage across Canada. McMaster Centre for Health Economics and Policy Analysis Research Working Paper 9808; September 1998.Google Scholar
6
6Menec, VH, MacWilliam, L, Sooden, RA, Mitchell, L. The health and health care use of Manitoba's seniors: have they changed over time?Winnipeg, MB: Manitoba Centre for Health Policy; 2002Google Scholar
7
7Soumerai, SB, Ross-Degnan, D, Avorn, J, McLaughlin, T, Choodnovskiy, I. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med1991;325:1072–7.CrossRefGoogle ScholarPubMed
8
8Tamblyn, R, Laprise, R, Hamley, JA, Abrahamowicz, M, Scott, S, Mayo, N, et al. . Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA2001;285:421–9.CrossRefGoogle ScholarPubMed
9
9Cox, ER, Henderson, RR. Prescription use behaviour among medicare beneficiaries with capped prescription benefits. J Managed Care Pharmacy2002;8:360–4.CrossRefGoogle ScholarPubMed
10
10Kozyrskyj, AL, Morgan, S, Dahl, M. Manitoba prescription cost data: an analysis for the Romanow Commission (unpublished data). Winnipeg, MB; September 2002.Google Scholar
11
11Willcox, SMM, Himmelstein, DU, Woolhandler, D. Inappropriate drug prescribing for the community-dwelling elderly. JAMA1994;272:292–6.CrossRefGoogle ScholarPubMed
12
12Tamblyn, RM, McLeod, PJ, Abrahamowicz, M, Monette, J, Gayton, DC, Berkson, L, et al. . Questionable prescribing for elderly patients in Quebec. CMAJ1994; 150: 1801–9.Google ScholarPubMed
13
13Mannesse, CK, Derkx, FHM, de Ridder, MAJ, Veld, AJM, van der Cammen, TJM. Contribution of adverse drug reactions to hospital admissions of older patients. Age Ageing2000;29:35–9.CrossRefGoogle ScholarPubMed
14
14Lipton, HL, Bero, LA, Bird, JA, McPhee, SJ. The impact of clinical pharmacists' consultations on physicians' geriatric drug prescribing: a randomized controlled trial. Med Care1992;30:646–58.CrossRefGoogle ScholarPubMed
15
15Anderson, GF, Hussey, PS. Population aging: a comparison among industrialized countries. Health Aff2000 May/June;19:191–203.CrossRefGoogle ScholarPubMed
16
16Romanow, RJ. Statement given on the release of the final report of the Commission on the Future of Health Care in Canada, National Press Theatre, Ottawa, November 28, 2002. http://www.healthcarecommission.ca/Google Scholar